$1.120
+0.010 (+0.90%)At close
BDMD News
BDMD Events
Baird Medical Receives Product Registrations in Pakistan
Baird Medical announced that the BD-GT Microwave Ablation System and T-1610 Disposable Microwave Ablation Needle have received product registrations from the Drug Regulatory Authority of Pakistan, further supporting the company's commercial activities in the country. The registrations build on Baird Medical's existing presence in Pakistan, where the company announced regulatory approvals and initial commercial availability at the Armed Forces Institute of Radiology & Imaging in January. Microwave ablation is increasingly being utilized as a minimally invasive treatment approach for benign and malignant soft tissue tumors, offering physicians the ability to precisely ablate targeted tissue while potentially reducing the burden associated with more invasive surgical procedures. Earlier this year, physicians in Vietnam and Argentina successfully completed their first microwave ablation procedures using Baird Medical's technology, demonstrating the progression from market entry to clinical utilization.
Baird Medical and Tianjin Yuanshan Medical Sign Strategic Cooperation Agreement
Baird Medical and Tianjin Yuanshan Medical announced the signing of a strategic cooperation agreement to establish a long-term partnership focused on global development and commercialization of next-generation IRE technologies. Under the partnership, the companies will initially collaborate on IRE, an advanced, non-thermal ablation technology that uses electrical pulses to destroy targeted tissue while preserving surrounding critical structures, such as blood vessels and nerves. Baird Medical and Alpmed plan to submit a 510 application for the first co-developed product to the FDA by the end of 2026, with the potential to receive regulatory clearance in 2027. The first device is intended for the ablation of soft tissue solid tumors in the liver, breast, thyroid, and prostate. Baird Medical will lead the global regulatory approval processes, including in the U.S., and holds worldwide commercialization rights for this IRE product.
Baird Medical Files $50M Mixed Securities Shelf
Baird Medical files $50M mixed securities shelf
Baird Medical Successfully Holds Clinical Training Workshops in Indonesia
Baird Medical Investment announced the successful execution of two clinical training workshops in Indonesia. This initiative supports the Company's strategic expansion in Southeast Asia by providing regional healthcare providers with the practical knowledge and advanced tools needed to enhance patient care.
Baird Medical Forms Strategic Partnership with Stonewood Key Capital
Baird Medical announced a strategic partnership with Stonewood Key Capital, a wholly-owned comprehensive investment management enterprise from New Zealand. This collaboration positions the Hainan Free Trade Port as a pivotal hub for the company's cross-border operations and supply chain. By capitalizing on the Free Trade Port's policies regarding cross-border capital flows and personnel mobility, the company aims to secure a competitive operational framework designed to meet rising demand for minimally invasive therapies addressing thyroid and other soft tissue applications.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.